Superworth

Research Alliance Corp III RACC

Drug Manufacturers - General, Healthcare
$10.10
−0.49%
Market cap
$91.9M
PE
n/m
one or more of the four quarters through 2026-06-30 missing
Forward PE
n/m
not a meaningful number
Price to sales
n/m
not a meaningful number
EV/EBIT
n/m
not a meaningful number
Revenue, 12 months
n/m
not a meaningful number
Net margin
n/m
not a meaningful number
Free cash flow yield
n/m
not a meaningful number

Charts

Financials

Income statement for RACC, by quarter
Income statementQ2 FY26
SG&A$184.4K
−$184.4K
Net income$54K
$0.01
1.4M

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Drug Manufacturers - General nearest Research Alliance Corp III's size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
RACCResearch Alliance Corp III$91.9Mn/mn/an/mn/mn/m
LFVNLifevantage$73.5M14.7×19.4×0.4×−20%2.8%
SPROSpero Therapeutics$60.6M9.5×9.5×1.3×−3%15.7%
ATNMActinium Pharmaceuticals$45M4.0×3.3×n/mn/mn/m
NATRNatures Sunshine Products$211.5M11.9×20.2×0.4×+7%3.7%
CRMDCorMedix$420.1M2.5×4.0×0.9×+281%40.5%
ARVNArvinas$491.7M47.0×50.5×1.6×−15%2.9%
PBYIPuma Biotechnology$525.5M19.6×12.3×2.3×−3%11.6%
IRWDIronwood Pharmaceuticals$571.7M4.5×14.8×1.5×+26%33.4%
ZVRAZevra Therapeutics$599.8M10.9×12.2×4.4×+119%42.8%
COLLCollegium Pharmaceutical$770.9M19.1×19.1×1.0×+14%5.9%
Peer median$455.9M11.4×13.5×1.3×+7%11.6%

More on Research Alliance Corp III

Its groups

About

Industry
Drug Manufacturers - General
Sector
Healthcare

Valuation data, not investment advice. Prices as of .